JP2009502135A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009502135A5 JP2009502135A5 JP2008522923A JP2008522923A JP2009502135A5 JP 2009502135 A5 JP2009502135 A5 JP 2009502135A5 JP 2008522923 A JP2008522923 A JP 2008522923A JP 2008522923 A JP2008522923 A JP 2008522923A JP 2009502135 A5 JP2009502135 A5 JP 2009502135A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- complex
- cargo compound
- transport
- cargo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 30
- 150000001875 compounds Chemical class 0.000 claims 20
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 210000004556 brain Anatomy 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 239000003153 chemical reaction reagent Substances 0.000 claims 3
- 108010092351 cupredoxin Proteins 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108010007337 Azurin Proteins 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 208000032612 Glial tumor Diseases 0.000 claims 2
- 206010018338 Glioma Diseases 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 238000002595 magnetic resonance imaging Methods 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 239000003053 toxin Substances 0.000 claims 2
- 231100000765 toxin Toxicity 0.000 claims 2
- 108700012359 toxins Proteins 0.000 claims 2
- 208000017194 Affective disease Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 206010010356 Congenital anomaly Diseases 0.000 claims 1
- 206010014967 Ependymoma Diseases 0.000 claims 1
- 208000003098 Ganglion Cysts Diseases 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 108090001030 Lipoproteins Proteins 0.000 claims 1
- 102000004895 Lipoproteins Human genes 0.000 claims 1
- 208000000172 Medulloblastoma Diseases 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 241000588653 Neisseria Species 0.000 claims 1
- 208000008846 Neurocytoma Diseases 0.000 claims 1
- 101150006573 PAN1 gene Proteins 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 108090000051 Plastocyanin Proteins 0.000 claims 1
- 108090000035 Pseudoazurin Proteins 0.000 claims 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000005400 Synovial Cyst Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 201000002785 amyotrophic lateral sclerosis type 11 Diseases 0.000 claims 1
- 230000008499 blood brain barrier function Effects 0.000 claims 1
- 210000001218 blood-brain barrier Anatomy 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 239000012830 cancer therapeutic Substances 0.000 claims 1
- 201000007455 central nervous system cancer Diseases 0.000 claims 1
- 208000025997 central nervous system neoplasm Diseases 0.000 claims 1
- 239000002872 contrast media Substances 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000000975 dye Substances 0.000 claims 1
- 239000002961 echo contrast media Substances 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 201000008361 ganglioneuroma Diseases 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 238000003384 imaging method Methods 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000000185 intracerebroventricular administration Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 230000002601 intratumoral effect Effects 0.000 claims 1
- 230000009545 invasion Effects 0.000 claims 1
- 210000005171 mammalian brain Anatomy 0.000 claims 1
- 206010027191 meningioma Diseases 0.000 claims 1
- 239000011859 microparticle Substances 0.000 claims 1
- 238000000386 microscopy Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 230000004112 neuroprotection Effects 0.000 claims 1
- 239000002405 nuclear magnetic resonance imaging agent Substances 0.000 claims 1
- 206010073131 oligoastrocytoma Diseases 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 108010086158 rusticyanin Proteins 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 206010062261 spinal cord neoplasm Diseases 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 238000002604 ultrasonography Methods 0.000 claims 1
- 238000012285 ultrasound imaging Methods 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70029705P | 2005-07-19 | 2005-07-19 | |
| US11/244,105 US7691383B2 (en) | 2004-10-07 | 2005-10-06 | Cupredoxin derived transport agents and methods of use thereof |
| US81851006P | 2006-07-06 | 2006-07-06 | |
| PCT/US2006/028022 WO2007012004A2 (en) | 2005-07-19 | 2006-07-19 | Transport agents for crossing the blood-brain barrier and into brain cancer cells, and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009502135A JP2009502135A (ja) | 2009-01-29 |
| JP2009502135A5 true JP2009502135A5 (https=) | 2009-09-10 |
Family
ID=37669545
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008522923A Pending JP2009502135A (ja) | 2005-07-19 | 2006-07-19 | 血液脳関門を越えるための、および脳癌細胞内への輸送因子、並びにその使用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US7807183B2 (https=) |
| EP (1) | EP1904642A4 (https=) |
| JP (1) | JP2009502135A (https=) |
| KR (1) | KR20080042804A (https=) |
| AU (1) | AU2006269879A1 (https=) |
| BR (1) | BRPI0615562A2 (https=) |
| CA (1) | CA2615617A1 (https=) |
| IL (1) | IL188719A0 (https=) |
| MX (1) | MX2008000994A (https=) |
| NO (1) | NO20080830L (https=) |
| WO (1) | WO2007012004A2 (https=) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7381701B2 (en) | 2001-02-15 | 2008-06-03 | The Borad Of Trustees Of The University Of Illinois | Compositions and methods for treating conditions related to ephrin signaling with cupredoxins |
| US7491394B2 (en) | 2001-02-15 | 2009-02-17 | The Board Of Trustees Of The University Of Illinois | Cytotoxic factors for modulating cell death |
| WO2004060403A2 (en) * | 2003-01-06 | 2004-07-22 | Angiochem Inc. | Aprotinin and anglos as carriers across the blood-brain barrier |
| US10675326B2 (en) | 2004-10-07 | 2020-06-09 | The Board Of Trustees Of The University Of Illinois | Compositions comprising cupredoxins for treating cancer |
| ES2744225T3 (es) | 2005-07-15 | 2020-02-24 | Angiochem Inc | Uso de polipéptidos de aprotinina como portadores en conjugados farmacéuticos |
| CA2615617A1 (en) * | 2005-07-19 | 2007-01-25 | The Board Of Trustees Of The University Of Illinois | Transport agents for crossing the blood-brain barrier and into brain cancer cells, and methods of use thereof |
| JP2010502765A (ja) * | 2006-09-11 | 2010-01-28 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ | キュプレドキシン由来ペプチドの修飾及びそれを使用する方法 |
| JP2010511408A (ja) | 2006-12-04 | 2010-04-15 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ | 癌をＣｐＧリッチＤＮＡおよびキュプレドキシンで治療するための組成物および方法 |
| JP2010518123A (ja) * | 2007-02-08 | 2010-05-27 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ | 癌をキュプレドキシンで予防するための組成物および方法 |
| US9365634B2 (en) * | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
| EP2200649A4 (en) | 2007-10-19 | 2012-09-26 | Univ California | COMPOSITIONS AND METHODS FOR TREATING CNS INFUSION, PSYCHOSIS, DELIRE, PTSD OR PTSS |
| KR101810799B1 (ko) * | 2008-02-01 | 2017-12-19 | 더 제너럴 하스피탈 코포레이션 | 의학적 질환 및 병태의 진단, 예후, 및 치료에 있어서 미세소포체의 용도 |
| MX355683B (es) | 2008-04-18 | 2018-04-26 | Angiochem Inc | Composiciones farmacéuticas de paclitaxel, análogos de paclitaxel o conjugados de paclitaxel, y métodos relacionados de preparación y uso. |
| WO2010043049A1 (en) | 2008-10-15 | 2010-04-22 | Angiochem Inc. | Etoposide and doxorubicin conjugates for drug delivery |
| CA2740316A1 (en) | 2008-10-15 | 2010-04-22 | Angiochem Inc. | Conjugates of glp-1 agonists and uses thereof |
| CA2745524C (en) | 2008-12-05 | 2020-06-09 | Angiochem Inc. | Conjugates of neurotensin or neurotensin analogs and uses thereof |
| US8853353B2 (en) | 2008-12-17 | 2014-10-07 | Angiochem, Inc. | Membrane type-1 matrix metalloprotein inhibitors and uses thereof |
| MX2011011023A (es) | 2009-04-20 | 2012-01-20 | Angiochem Inc | Tratamiento de cancer de ovarios usando un agente anti-cancer conjugado con un analogo de angiopep-2. |
| RU2012103240A (ru) | 2009-07-02 | 2013-08-10 | Ангиокем Инк. | Мультимерные пептидные конъюгаты и их применение |
| EP3000481A3 (en) | 2009-07-14 | 2016-05-11 | Mayo Foundation for Medical Education and Research | Peptide-mediated non-covalent delivery of active agent agents across the blood brain barrier |
| US20130029339A1 (en) | 2009-09-09 | 2013-01-31 | The General Hospital Corporation | Use of microvesicles in analyzing kras mutations |
| EP2475988B1 (en) | 2009-09-09 | 2018-11-14 | The General Hospital Corporation | Use of microvesicles in analyzing nucleic acid profiles |
| WO2012031008A2 (en) | 2010-08-31 | 2012-03-08 | The General Hospital Corporation | Cancer-related biological materials in microvesicles |
| WO2012059593A1 (en) * | 2010-11-05 | 2012-05-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Vaccines for preventing meningococcal infections |
| CA2817111C (en) | 2010-11-10 | 2019-03-05 | Exosome Diagnostics, Inc. | Method for isolation of nucleic acid containing particles and extraction of nucleic acids therefrom |
| WO2013086207A1 (en) * | 2011-12-06 | 2013-06-13 | The Ohio State University | Non-ionic, low osmolar contrast agents for delivery of antisense oligonucleotides and treatment of disease |
| WO2014016152A1 (en) | 2012-07-27 | 2014-01-30 | Institut National De La Sante Et De La Recherche Medicale | Cd147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia |
| JP2015526434A (ja) | 2012-08-14 | 2015-09-10 | アンジオケム インコーポレーテッド | ペプチド−デンドリマーコンジュゲート及びその使用 |
| KR102166549B1 (ko) * | 2014-01-10 | 2020-10-16 | 주식회사 젬백스앤카엘 | 혈뇌장벽 투과성 펩티드 및 이를 포함하는 컨쥬게이트 |
| JP2017506884A (ja) * | 2014-01-17 | 2017-03-16 | ウェイク・フォレスト・ユニヴァーシティ・ヘルス・サイエンシズ | 活性薬の送達を増強するための方法 |
| US10039808B2 (en) | 2014-10-22 | 2018-08-07 | Michael Chez | Method of treating or improving neurological function in a human subject |
| US9925244B1 (en) | 2015-02-17 | 2018-03-27 | Michael Chez | Treatment of warts in non-immunosuppressed patients |
| WO2016176573A1 (en) | 2015-04-30 | 2016-11-03 | Board Of Regents, The University Of Texas System | Antibacterial polypeptide libraries and methods for screening the same |
| EP3307326B9 (en) | 2015-06-15 | 2021-02-24 | Angiochem Inc. | Methods for the treatment of leptomeningeal carcinomatosis |
| US10072065B2 (en) | 2015-08-24 | 2018-09-11 | Mayo Foundation For Medical Education And Research | Peptide-mediated delivery of immunoglobulins across the blood-brain barrier |
| US11752315B1 (en) | 2016-10-07 | 2023-09-12 | Carlos A. Hakim | Method of treating normal pressure hydrocephalus |
| US10688191B2 (en) | 2018-01-19 | 2020-06-23 | Hr Biomed, Llc | Delivery of a chemotherapy agent across the blood-brain barrier |
| WO2020172515A1 (en) * | 2019-02-22 | 2020-08-27 | The Trustees Of Columbia University In The City Of New York | Preparing tissues for delivery of therapeutic and diagnostic agents and delivering the agents |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5827934A (en) | 1988-03-08 | 1998-10-27 | The University Of Wyoming | Cytotoxic diphtheria toxin fragments |
| US5972899A (en) | 1996-01-25 | 1999-10-26 | New York University | Apoptosis induced by Shigella IpaB |
| ATE452185T1 (de) | 1999-01-26 | 2010-01-15 | Univ London | Dimethylarginin-dimethylaminohydrolasen |
| US6800437B1 (en) * | 1999-08-06 | 2004-10-05 | Tibotec Bvba | Method of monitoring a biological system by labeling with an apo metal binding protein |
| US20020164703A1 (en) | 2000-12-21 | 2002-11-07 | Krzysztof Pawlowski | Card-domain containing polypeptides, encoding nucleic acids, and methods of use |
| GB0103424D0 (en) * | 2001-02-12 | 2001-03-28 | Chiron Spa | Gonococcus proteins |
| JP4881536B2 (ja) * | 2001-02-15 | 2012-02-22 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ | 細胞死を調節する細胞障害性因子 |
| US7301010B2 (en) * | 2001-02-15 | 2007-11-27 | The Board Of Trustees Of The University Of Illinois | Compositions and methods for treating HIV infection with cupredoxin and cytochrome c |
| US7491394B2 (en) | 2001-02-15 | 2009-02-17 | The Board Of Trustees Of The University Of Illinois | Cytotoxic factors for modulating cell death |
| US7338766B2 (en) * | 2001-02-15 | 2008-03-04 | The Board Of Trustees Of The University Of Illinois | Compositions and methods for treating malaria with cupredoxin and cytochrome |
| JP2005518182A (ja) * | 2001-03-02 | 2005-06-23 | フロリジーン リミティド | 細胞の視覚的特徴を修飾する配列 |
| GB0211295D0 (en) | 2002-05-16 | 2002-06-26 | Univ London | Treatment of pain |
| EP1562982B1 (en) | 2002-11-15 | 2010-05-05 | Novartis Vaccines and Diagnostics S.r.l. | Unexpected surface proteins in neisseria meningitidis |
| EA200700813A1 (ru) | 2004-10-07 | 2008-10-30 | Ананда Чакрабарти | Транспортирующие вещества, производные купредоксина и способы их применения |
| US7377597B2 (en) | 2005-02-15 | 2008-05-27 | Geo Plastics | Wheel assembly having wheel-mounting sleeve and retainer |
| AU2006277009A1 (en) | 2005-05-20 | 2007-02-15 | The Board Of Trustees Of The University Of Illinois | Compositions and methods for treating conditions related to ephrin signaling with cupredoxins |
| EP1883650A4 (en) | 2005-05-20 | 2009-06-10 | Univ Illinois | COMPOSITIONS AND METHODS FOR TREATING HIV INFECTION USING CUPREDOXIN AND CYTOCHROME C |
| EP1882039A4 (en) | 2005-05-20 | 2008-08-20 | Univ Illinois | COMPOSITIONS AND METHODS FOR TREATING MALARIA USING CUPREDOXINS AND CYTOCHROMES |
| CA2615617A1 (en) * | 2005-07-19 | 2007-01-25 | The Board Of Trustees Of The University Of Illinois | Transport agents for crossing the blood-brain barrier and into brain cancer cells, and methods of use thereof |
| JP2010502765A (ja) | 2006-09-11 | 2010-01-28 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ | キュプレドキシン由来ペプチドの修飾及びそれを使用する方法 |
| EP2061498A4 (en) | 2006-09-14 | 2009-11-04 | Univ Illinois | COMPOSITIONS AND METHOD FOR CANCER PREPARATION WITH CUPREDOXINES |
| JP2010518123A (ja) | 2007-02-08 | 2010-05-27 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ | 癌をキュプレドキシンで予防するための組成物および方法 |
| WO2009078977A2 (en) | 2007-12-14 | 2009-06-25 | Cdg Therapeutics Inc | Compositions and methods to concurrently treat or prevent multiple diseases with cupredoxins |
| GB0802126D0 (en) | 2008-02-05 | 2008-03-12 | Level 5 Networks Inc | Scalable sockets |
-
2006
- 2006-07-19 CA CA002615617A patent/CA2615617A1/en not_active Abandoned
- 2006-07-19 BR BRPI0615562-6A patent/BRPI0615562A2/pt not_active IP Right Cessation
- 2006-07-19 US US11/488,695 patent/US7807183B2/en not_active Expired - Fee Related
- 2006-07-19 EP EP06787848A patent/EP1904642A4/en not_active Withdrawn
- 2006-07-19 MX MX2008000994A patent/MX2008000994A/es active IP Right Grant
- 2006-07-19 WO PCT/US2006/028022 patent/WO2007012004A2/en not_active Ceased
- 2006-07-19 JP JP2008522923A patent/JP2009502135A/ja active Pending
- 2006-07-19 KR KR1020087002479A patent/KR20080042804A/ko not_active Ceased
- 2006-07-19 AU AU2006269879A patent/AU2006269879A1/en not_active Abandoned
-
2008
- 2008-01-10 IL IL188719A patent/IL188719A0/en unknown
- 2008-02-15 NO NO20080830A patent/NO20080830L/no not_active Application Discontinuation
-
2010
- 2010-10-04 US US12/897,298 patent/US8188251B2/en not_active Expired - Lifetime
-
2012
- 2012-05-25 US US13/481,018 patent/US8545812B2/en not_active Expired - Fee Related
-
2013
- 2013-09-30 US US14/041,184 patent/US9309292B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009502135A5 (https=) | ||
| CN113908431B (zh) | 使用交变电场来提高血脑屏障的通透性 | |
| Silva et al. | Combination of cell-penetrating peptides with nanoparticles for therapeutic application: a review | |
| EP2282763B1 (en) | Process for preparing supramolecular calcitonin assemblies (SCA) | |
| Dhuria et al. | Intranasal drug targeting of hypocretin-1 (orexin-A) to the central nervous system | |
| US9597408B2 (en) | Peptide-mediated non-covalent delivery of active agents across the blood-brain barrier | |
| Ksendzovsky et al. | Convection-enhanced delivery of M13 bacteriophage to the brain | |
| US20240398978A1 (en) | Compositions and Methods for Treating Dopamine Disorders | |
| US20200317734A1 (en) | Amyloid-beta-binding peptides and the use thereof for the treatment and diagnosis of alzheimer's disease | |
| Ding et al. | Image-guided drug delivery to the brain using nanotechnology | |
| WO2018106273A1 (en) | Collagen targeting nanofibers and nanosheets | |
| Karande et al. | Novel approaches for the delivery of biologics to the central nervous system | |
| Mi et al. | Constructed transferrin receptor-targeted liposome for the delivery of fluvoxamine to improve prognosis in a traumatic brain injury mouse model | |
| Ebert et al. | Delivery of neuroregenerative proteins to the brain for treatments of neurodegenerative brain diseases | |
| CN108101961A (zh) | 一种可以实现脑靶向递药的短肽及其应用 | |
| Casaca-Carreira et al. | Distribution and penetration of intracerebroventricularly administered 2′ OMePS oligonucleotide in the mouse brain | |
| Lawrence | William Pardridge discusses the lack of BBB research | |
| US20100310473A1 (en) | Targeting Brain Cells Via Ophthalmic Delivery | |
| Pardridge et al. | William Pardridge discusses the lack of BBB research | |
| Pathak et al. | Drug delivery to the brain: targeting technologies to deliver therapeutics to brain lesions | |
| RU2008106230A (ru) | Средства проникновения через гематоэнцефалический барьер и внутрь клеток раковой опухоли мозга и способы их использования | |
| Upadhaya et al. | Diagnostic and theranostic intranasal nanointerventions for brain diseases | |
| Patwekar et al. | Antibody-based nanoparticles in Alzheimer’s disease: innovations in diagnosis and therapy | |
| Rajkonwar et al. | Blood–Brain Barrier as a Point of Concern for Neural Drug Delivery: Problems and Advancements | |
| Mihaylova et al. | Current issues regarding approved peptide and protein drugs in Bulgaria |